Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA222630
Max Phase: Preclinical
Molecular Formula: C10H15FN3O7P
Molecular Weight: 339.22
Molecule Type: Small molecule
Associated Items:
ID: ALA222630
Max Phase: Preclinical
Molecular Formula: C10H15FN3O7P
Molecular Weight: 339.22
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C[C@@]1(F)[C@H](O)[C@@H](COP(=O)(O)O)O[C@H]1n1ccc(N)nc1=O
Standard InChI: InChI=1S/C10H15FN3O7P/c1-10(11)7(15)5(4-20-22(17,18)19)21-8(10)14-3-2-6(12)13-9(14)16/h2-3,5,7-8,15H,4H2,1H3,(H2,12,13,16)(H2,17,18,19)/t5-,7-,8-,10-/m1/s1
Standard InChI Key: MJKXCSWNCSKTGP-VPCXQMTMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 339.22 | Molecular Weight (Monoisotopic): 339.0632 | AlogP: -1.08 | #Rotatable Bonds: 4 |
Polar Surface Area: 157.13 | Molecular Species: ACID | HBA: 8 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 10 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 1.22 | CX Basic pKa: | CX LogP: -1.75 | CX LogD: -5.28 |
Aromatic Rings: 1 | Heavy Atoms: 22 | QED Weighted: 0.50 | Np Likeness Score: 1.13 |
1. Murakami E, Bao H, Ramesh M, McBrayer TR, Whitaker T, Micolochick Steuer HM, Schinazi RF, Stuyver LJ, Obikhod A, Otto MJ, Furman PA.. (2007) Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase., 51 (2): [PMID:17101674] [10.1128/aac.00400-06] |
2. Murakami E, Niu C, Bao H, Micolochick Steuer HM, Whitaker T, Nachman T, Sofia MA, Wang P, Otto MJ, Furman PA.. (2008) The mechanism of action of beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine involves a second metabolic pathway leading to beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase., 52 (2): [PMID:17999967] [10.1128/aac.01184-07] |
3. Murakami E, Bao H, Mosley RT, Du J, Sofia MJ, Furman PA.. (2011) Adenosine deaminase-like protein 1 (ADAL1): characterization and substrate specificity in the hydrolysis of N(6)- or O(6)-substituted purine or 2-aminopurine nucleoside monophosphates., 54 (16): [PMID:21755941] [10.1021/jm200650j] |
Source(1):